StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) stock

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$584.10−3.78 (-0.64%)

Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –

United Therapeutics total assets

Total assets on the balance sheet at the end of each period.

United Therapeutics's total assets was $7.22B at Jun 30, 2026. For fiscal 2025 it was $7.88B, up 7.0% from the year before. Over ten years it grew 13.7% a year on average. The highest annual figure on record is $7.88B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.88B+7.0%
FY2024Dec 31, 2024$7.36B+2.7%
FY2023Dec 31, 2023$7.17B+18.6%
FY2022Dec 31, 2022$6.04B+16.9%
FY2021Dec 31, 2021$5.17B+12.0%
FY2020Dec 31, 2020$4.62B+17.9%
FY2019Dec 31, 2019$3.91B+15.1%
FY2018Dec 31, 2018$3.40B+18.1%
FY2017Dec 31, 2017$2.88B+23.8%
FY2016Dec 31, 2016$2.33B+6.5%
FY2015Dec 31, 2015$2.18B+15.9%
FY2014Dec 31, 2014$1.88B-9.7%
FY2013Dec 31, 2013$2.09B+28.3%
FY2012Dec 31, 2012$1.63B+7.1%
FY2011Dec 31, 2011$1.52B+6.0%
FY2010Dec 31, 2010$1.43B+36.1%
FY2009Dec 31, 2009$1.05B–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$7.22B-8.7%
Q1 FY2026Mar 31, 2026$6.71B-13.3%
Q4 FY2025Dec 31, 2025$7.88B+7.0%
Q3 FY2025Sep 30, 2025$7.35B+3.2%
Q2 FY2025Jun 30, 2025$7.91B+17.6%
Q1 FY2025Mar 31, 2025$7.74B+19.2%
Q4 FY2024Dec 31, 2024$7.36B+2.7%
Q3 FY2024Sep 30, 2024$7.12B+1.4%
Q2 FY2024Jun 30, 2024$6.72B+0.6%
Q1 FY2024Mar 31, 2024$6.50B+2.4%
Q4 FY2023Dec 31, 2023$7.17B+18.6%
Q3 FY2023Sep 30, 2023$7.02B+21.5%
Q2 FY2023Jun 30, 2023$6.68B+20.5%
Q1 FY2023Mar 31, 2023$6.35B+18.4%
Q4 FY2022Dec 31, 2022$6.04B+16.9%
Q3 FY2022Sep 30, 2022$5.78B+14.5%
Q2 FY2022Jun 30, 2022$5.54B+14.4%
Q1 FY2022Mar 31, 2022$5.36B+15.5%
Q4 FY2021Dec 31, 2021$5.17B+12.0%
Q3 FY2021Sep 30, 2021$5.05B+14.5%
Q2 FY2021Jun 30, 2021$4.84B+14.8%
Q1 FY2021Mar 31, 2021$4.64B+15.3%
Q4 FY2020Dec 31, 2020$4.62B+17.9%
Q3 FY2020Sep 30, 2020$4.41B+10.3%
Q2 FY2020Jun 30, 2020$4.22B+8.2%
Q1 FY2020Mar 31, 2020$4.03B+8.0%
Q4 FY2019Dec 31, 2019$3.91B+15.1%
Q3 FY2019Sep 30, 2019$4.00B+17.2%
Q2 FY2019Jun 30, 2019$3.90B+20.2%
Q1 FY2019Mar 31, 2019$3.73B+23.4%
Q4 FY2018Dec 31, 2018$3.40B+18.1%
Q3 FY2018Sep 30, 2018$3.41B+16.2%
Q2 FY2018Jun 30, 2018$3.24B+20.6%
Q1 FY2018Mar 31, 2018$3.02B+17.9%
Q4 FY2017Dec 31, 2017$2.88B+23.8%
Q3 FY2017Sep 30, 2017$2.94B+29.4%
Q2 FY2017Jun 30, 2017$2.69B–
Q1 FY2017Mar 31, 2017$2.56B–
Q4 FY2016Dec 31, 2016$2.33B–
Q3 FY2016Sep 30, 2016$2.27B–

More United Therapeutics figures

See a number that looks wrong?